2024 |
Le Teuff G, Cozic N, Boyer J-C, Boige V, Diasio RB, Taieb J, et al., 'Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis', BRITISH JOURNAL OF CANCER, [C1]
|
|
|
2024 |
Paul CL, Verrills NM, Ackland S, Scott R, Goode S, Thomas A, et al., 'The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology.', BMC Health Serv Res, 24 320 (2024) [C1]
|
|
Nova |
2023 |
White C, Scott RJ, Paul C, Ackland S, 'Reply to "Implementation of DPYD Genotyping in Admixed American Populations: Brazil as a Model Case"', CLINICAL PHARMACOLOGY & THERAPEUTICS, 114 25-25 (2023)
|
|
|
2023 |
Lee J, Dean A, Price T, Sjoquist K, Gebski V, Mumford J, et al., 'ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial', ESMO Gastrointestinal Oncology, 1 3-8 (2023)
|
|
|
2023 |
M Naeini M, Newell F, Aoude LG, Bonazzi VF, Patel K, Lampe G, et al., 'Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy', Nature Communications, 14 (2023) [C1]
Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and... [more]
Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients mostly from the DOCTOR phase II clinical trial (Australian New Zealand Clinical Trials Registry-ACTRN12609000665235), with exploratory analysis pre-specified in the study protocol of the trial. We report genomic features associated with poorer overall survival, such as the APOBEC mutational and RS3-like rearrangement signatures. We also show that positron emission tomography non-responders have more sub-clonal genomic copy number alterations. Transcriptomic analysis categorises patients into four immune clusters correlated with survival. The immune suppressed cluster is associated with worse survival, enriched with myeloid-derived cells, and an epithelial-mesenchymal transition signature. The immune hot cluster is associated with better survival, enriched with lymphocytes, myeloid-derived cells, and an immune signature including CCL5, CD8A, and NKG7. The immune clusters highlight patients who may respond to immunotherapy and thus may guide future clinical trials.
|
|
|
2022 |
White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Fox SB, et al., 'Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront
|
|
Nova |
2022 |
Mercieca-Bebber R, Barnes EH, Wilson K, Samoon Z, Walpole E, Mai T, et al., 'Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma', BMC Cancer, 22 (2022) [C1]
Background: AGITG DOCTOR was a randomised phase 2 trial of pre-operative cisplatin, 5 fluorouracil (CF) followed by docetaxel (D) with or without radiotherapy (RT) based on poor e... [more]
Background: AGITG DOCTOR was a randomised phase 2 trial of pre-operative cisplatin, 5 fluorouracil (CF) followed by docetaxel (D) with or without radiotherapy (RT) based on poor early response to CF, detected via PET, for resectable oesophageal adenocarcinoma. This study describes PROs over 2 years. Methods: Participants (N¿= 116) completed the EORTC QLQ-C30 and oesophageal module (QLQ-OES18) before chemotherapy (baseline), before surgery, six and 12 weeks post-surgery and three-monthly until 2 years. We plotted PROs over time and calculated the percentage of participants per treatment group whose post-surgery score was within 10 points (threshold for clinically relevant change) of their baseline score, for each PRO scale. We examined the relationship between Grade 3+ adverse events (AEs) and PROs. This analysis included four groups: CF responders, non-responders randomised to DCF, non-responders randomised to DCF + RT, and ¿others¿ who were not randomised. Results: Global QOL was clinically similar between groups from 6 weeks post-surgery. All groups had poorer functional and higher symptom scores during active treatment and shortly after surgery, particularly the DCF and DCF + RT groups. DCF + RT reported a clinically significant difference (-13points) in mean overall health/QOL between baseline and pre-surgery. Similar proportions of patients across groups scored +/- 10 points of baseline scores within 2 years for most PRO domains. Instance of grade 3+ AEs were not related to PROs at baseline or 2 years. Conclusions: By 2 years, similar proportions of patients scored within 10 points of baseline for most PRO domains, with the exception of pain and insomnia for the DCF + RT group. Non-responders randomised to DCF or DCF + RT experienced additional short-term burden compared to CF responders, reflecting the longer duration of neoadjuvant treatment and additional toxicity. This should be weighed against clinical benefits reported in AGITG DOCTOR. This data will inform communication of the trajectory of treatment options for early CF non-responders. Trial registration: Australia New Zealand Clinical Trials Registry (ANZCTR), ACTRN12609000665235. Registered 31 July 2009.
|
|
Nova |
2022 |
White C, Scott R, Paul CL, Ackland SP, 'Pharmacogenomics in the era of personalised medicine', MEDICAL JOURNAL OF AUSTRALIA, 217 510-513 (2022)
|
|
|
2021 |
White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Ackland S, 'Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature', PHARMACOGENOMICS & PERSONALIZED MEDICINE, 14 1603-1617 (2021) [C1]
|
|
Nova |
2021 |
Dunn C, Hong W, Gibbs P, Ackland S, Sjoquist K, Tebbutt NC, et al., 'Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group', CLINICAL COLORECTAL CANCER, 20 245-255 (2021) [C1]
|
|
Nova |
2020 |
Ardolino L, Hansen A, Ackland S, Joshua A, 'Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies', Hormones and Cancer, 11 155-169 (2020) [C1]
|
|
Nova |
2020 |
Barbour AP, Walpole ET, Mai GT, Barnes EH, Watson DI, Ackland SP, et al., 'Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial', Annals of Oncology, 31 236-245 (2020) [C1]
Background: Patients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) to chemotherapy have poorer survival and histolog... [more]
Background: Patients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) to chemotherapy have poorer survival and histological response rates <5%. We investigated whether tailoring neoadjuvant therapy can improve outcomes in these patients. Patients and methods: Patients with resectable EAC were enrolled and randomised into two single-arm, multicentre phase II trials. After induction cisplatin and 5-fluorouracil (CF), all were assessed by day 15 positron emission tomography (PET). Patients with an EMR [maximum standardised uptake values (SUVmax) =35% reduction from baseline to day 15 PET] received a second CF cycle then oesophagectomy. Non-responders were randomised 1: 1 to two cycles of CF and docetaxel (DCF, n = 31) or DCF + 45 Gy radiotherapy (DCFRT, n = 35) then oesophagectomy. The primary end point was major histological response (<10% residual tumour) in the oesophagectomy specimen; secondary end points were overall survival (OS), progression-free survival (PFS), and locoregional recurrence (LR). Results: Of 124 patients recruited, major histological response was achieved in 3/45 (7%) with EMR, 6/30 (20%) DCF, and 22/35 (63%) DCFRT patients. Grade 3/4 toxicities occurred in 12/45 (27%) EMR (CF), 13/31 (42%) DCF, and 25/35 (71%) DCFRT patients. No treatment-related deaths occurred. LR by 3 years was seen in 5/45 (11%) EMR, 10/31 (32%) DCF, and 4/35 (11%) DCFRT patients. PFS [95% confidence interval (CI)] at 36 months was 47% (31% to 61%) for EMR, 29% (15% to 45%) for DCF, and 46% (29% to 61%) for DCFRT patients. OS (95% CI) at 60 months was 53% (37% to 67%) for EMR, 31% (16% to 48%) for DCF, and 46% (29% to 61%) for DCFRT patients. Conclusions: EMR is associated with favourable OS, PFS, and low LR. For non-responders, the addition of docetaxel augmented histological response rates, but OS, PFS, and LR remained inferior compared with responders. DCFRT improved histological response and PFS/LR outcomes, matching the EMR group. Early PET/CT has the potential to tailor therapy for patients not showing an early response to chemotherapy. Trial registration: ACTRN12609000665235.
|
|
Nova |
2020 |
Ackland SP, Michael M, de Souza P, Martin JH, Clarke SJ, Francis K, et al., 'Science and art of anticancer drug dosing: nine steps to personalised therapy', INTERNAL MEDICINE JOURNAL, 50 992-996 (2020)
|
|
|
2019 |
Clingan PR, Ackland SP, Brungs D, de Souza P, Aghmesheh M, Garg MB, et al., 'First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15 151-157 (2019)
|
|
|
2019 |
Jameson MB, Gormly K, Espinoza D, Hague W, Asghari G, Jeffery GM, et al., 'SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial', BMC CANCER, 19 (2019)
|
|
|
2019 |
Ackland SP, Gebski V, Zdenkowski N, Wilson A, Green M, Tees S, et al., 'Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311', Breast Cancer Research and Treatment, 176 357-365 (2019) [C1]
Purpose: The separate impacts of dose and dose intensity of chemotherapy for metastatic breast cancer remain uncertain. The primary objective of this trial was to compare a short,... [more]
Purpose: The separate impacts of dose and dose intensity of chemotherapy for metastatic breast cancer remain uncertain. The primary objective of this trial was to compare a short, high-dose, intensive course of epirubicin and cyclophosphamide (EC) with a longer conventional dose regimen delivering the same total dose of chemotherapy. Methods: This open label trial randomised 235 women with metastatic breast cancer to receive either high-dose epirubicin 150¿mg/m2 and cyclophosphamide 1500¿mg/m2 with filgrastim support every 3 weeks for 3 cycles (HDEC) or standard dose epirubicin 75¿mg/m2 and cyclophosphamide 750¿mg/m2 every 3 weeks for 6 cycles (SDEC). Primary outcomes were time to progression, overall survival and quality of life. Results: In 118 patients allocated HDEC 90% of the planned dose was delivered, compared to 96% in the 117 participants allocated SDEC. There were no significant differences in the time to disease progression (5.7 vs. 5.8 months, P = 0.19) or overall survival (14.5 vs. 16.5 months, P = 0.29) between HDEC and SDEC, respectively. Patients on HDEC reported worse quality of life during therapy, but scores improved after completion to approximate those reported by patients allocated SDEC. Objective tumour response was recorded in 33 (28%) on HDEC and 42 patients (36%) on SDEC. HDEC produced more haematologic toxicity. Conclusion: For women with metastatic breast cancer, disease progression, survival or quality of life were no better with high-dose intensity compared to standard dose EC chemotherapy. Australian Clinical Trials Registry registration number ACTRN12605000478617.
|
|
Nova |
2017 |
Ansari N, Solomon MJ, Fisher RJ, Mackay J, Burmeister B, Ackland S, et al., 'Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum Trans-Tasman Radiation Oncology Group Trial (TROG 01.04)', ANNALS OF SURGERY, 265 882-888 (2017)
|
|
|
2017 |
Ackland SP, Shi Y, 'Quality publishing', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 13 5-5 (2017)
|
|
|
2016 |
Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, et al., 'Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: The AFFIRM study', Annals of Oncology, 27 1273-1279 (2016) [C1]
Background: The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progres... [more]
Background: The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC. Patients and methods: Patients with mCRC were randomized to receive first-line therapy with mFOLFOX6 plus aflibercept (4 mg/kg) or mFOLFOX6 alone. The primary end point of this phase II study was the progression-free survival (PFS) rate at 12 months in each arm. The analysis of efficacy between the arms was a pre-planned secondary analysis. Results: Of 236 randomized patients, 227 and 235 patients were evaluable for the primary efficacy analysis and safety, respectively. The probabilities of being progression-free at 12 months were 25.8% [95% confidence interval (CI) 17.2- 34.4] for the aflibercept/mFOLFOX6 arm and 21.2% (95% CI 12.2-30.3) for the mFOLFOX6 arm. The median PFS was 8.48 months (95% CI 7.89-9.92) for the aflibercept/mFOLFOX6 arm and 8.77 months (95% CI 7.62-9.27) for the mFOLFOX6 arm; the hazard ratio of aflibercept/mFOLFOX6 versus mFOLFOX6 was 1.00 (95% CI 0.74-1.36). The response rates were 49.1% (95% CI 39.7-58.6) and 45.9% (95% CI 36.4-55.7) for patients treated with and without aflibercept, respectively. The most frequent treatment-emergent grade 3/4 adverse events (AEs) excluding laboratory abnormalities reported for aflibercept/mFOLFOX6 versus mFOLFOX6 were neuropathy (16.8% versus 17.2%) and diarrhea (13.4% versus 5.2%). Neutropenia grade 3/4 occurred in 36.1% versus 29.3%. The most common vascular endothelial growth factor inhibition class-effect grade 3/4 AEs for aflibercept/mFOLFOX6 versus mFOLFOX6 were hypertension (35.3% versus 1.7%), proteinuria (9.2% versus 0%), deep vein thrombosis (5.9% versus 0.9%) and pulmonary embolism (5.9% versus 5.2%). Conclusion: No difference in PFS rate was observed between treatment groups. Adding aflibercept to first-line mFOLFOX6 did not increase efficacy but was associated with higher toxicity.
|
|
Nova |
2016 |
McLachlan SA, Fisher RJ, Zalcberg J, Solomon M, Burmeister B, Goldstein D, et al., 'The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)', European Journal of Cancer, 55 15-26 (2016) [C1]
Purpose To assess health-related quality of life (HRQOL) in patients participating in a randomised trial of neoadjuvant short course radiation (SC) or long course chemoradiation (... [more]
Purpose To assess health-related quality of life (HRQOL) in patients participating in a randomised trial of neoadjuvant short course radiation (SC) or long course chemoradiation (LC) for operable rectal cancer. Patients and methods Eligible patients with T3N0-2M0 rectal cancer completed the European Organisation for Research and Treatment of Cancer quality of life questionnaire (QLQ-C30) and the colorectal cancer specific module (QLQ C38) at randomisation and 1, 2, 3, 6, 9 and 12 months later. Results Of 326 patients randomised, 297 (SC 143, LC 154) were eligible for completion of HRQOL questionnaires. Baseline scores were comparable across the SC and LC groups. Patients reported low scores on sexual functioning and sexual enjoyment. Defaecation problems were the worst of the symptoms at baseline. Surgery had the most profoundly negative effect on HRQOL, seen in both the SC and LC treatment groups to the same extent. The most severely affected domains were physical function and role function and the most severely affected symptoms were fatigue, pain, appetite, weight loss and male sexual problems. Most domains and symptoms returned to baseline levels by 12 months apart from body image, sexual enjoyment and male sexual problems. Future perspective was better than prior to treatment. Conclusion There is no overall difference in HRQOL between SC and LC neoadjuvant treatment strategies, in the first 12 months, after surgery. In the immediate postoperative period HRQOL was adversely affected in both groups but for the most part was temporary. Some residual sexual functioning concerns persisted at 12 months.
|
|
Nova |
2016 |
Fradgley EA, Paul CL, Bryant J, Collins N, Ackland SP, Bellamy D, Levi CR, 'Collaborative Patient-Centered Quality Improvement: A Cross-Sectional Survey Comparing the Types and Numbers of Quality Initiatives Selected by Patients and Health Professionals.', Eval Health Prof, 39 475-495 (2016) [C1]
|
|
Nova |
2016 |
Barbour A, Walpole E, Mai GT, Chan H, Barnes E, Watson D, et al., 'An AGITG trial A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel +/-radioTherapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma', Annals of Oncology, 27 vi207 (2016)
|
|
|
2016 |
Ackland S, Shi Y-K, 'Biomedical publishing in 2015 and beyond: challenges and opportunities', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 12 5-6 (2016)
|
|
|
2016 |
Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, et al., 'INPP4B is an oncogenic regulator in human colon cancer', Oncogene, 35 3049-3061 (2016) [C1]
Inositol polyphosphate 4-phosphatase type II (INPP4B) negatively regulates phosphatidylinositol 3-kinase signaling and is a tumor suppressor in some types of cancers. However, we ... [more]
Inositol polyphosphate 4-phosphatase type II (INPP4B) negatively regulates phosphatidylinositol 3-kinase signaling and is a tumor suppressor in some types of cancers. However, we have found that it is frequently upregulated in human colon cancer cells. Here we show that silencing of INPP4B blocks activation of Akt and serum-and glucocorticoid-regulated kinase 3 (SGK3), inhibits colon cancer cell proliferation and retards colon cancer xenograft growth. Conversely, overexpression of INPP4B increases proliferation and triggers anchorage-independent growth of normal colon epithelial cells. Moreover, we demonstrate that the effect of INPP4B on Akt and SGK3 is associated with inactivation of phosphate and tensin homolog through its protein phosphatase activity and that the increase in INPP4B is due to Ets-1-mediated transcriptional upregulation in colon cancer cells. Collectively, these results suggest that INPP4B may function as an oncogenic driver in colon cancer, with potential implications for targeting INPP4B as a novel approach to treat this disease.
|
|
Nova |
2016 |
Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, et al., 'Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial', Journal of Neuro-Oncology, 128 163-171 (2016) [C1]
Newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter has a poor prognosis, with a median survival of 12¿months. This phase II study investigated the efficacy an... [more]
Newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter has a poor prognosis, with a median survival of 12¿months. This phase II study investigated the efficacy and safety of combining the selective integrin inhibitor cilengitide with a combination of metronomic temozolomide and procarbazine for these patients. Eligible patients (newly diagnosed, histologically confirmed supratentorial glioblastoma with unmethylated MGMT promoter) were entered into this multicentre study. Cilengitide (2000¿mg IV twice weekly) was commenced 1¿week prior to radiotherapy combined with daily temozolomide (60¿mg/m2) and procarbazine (50 or 100¿mg) and, after 4¿weeks¿ break, followed by six adjuvant cycles of temozolomide (50¿60¿mg/m2) and procarbazine (50 or 100¿mg) on days 1¿20, every 28¿days. Cilengitide was continued for up to 12¿months or until disease progression or unacceptable toxicity. The primary endpoint for efficacy was a 12-month overall survival rate of 65¿%. Twenty-nine patients completed study treatment. Sixteen patients survived for 12¿months or more, an overall survival rate of 55¿%.¿The median overall survival was 14.5¿months (95¿% CI 11.1¿19.6) and the median progression-free survival was 7.4¿months (95¿% CI 6.1¿8). Cilengitide combined with metronomic temozolomide and procarbazine in MGMT-promoter unmethylated glioblastoma did not improve survival compared with historical data and does not warrant further investigation.
|
|
Nova |
2015 |
Bryant J, Sanson-Fisher R, Fradgley E, Regan T, Hobden B, Ackland SP, 'Oncology patients overwhelmingly support tissue banking.', BMC Cancer, 15 413 (2015) [C1]
|
|
Nova |
2014 |
Yip D, Zalcberg J, Ackland S, Barbour AP, Desai J, Fox S, et al., 'Controversies in the management of gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, 10 216-227 (2014) [C1]
Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primar... [more]
Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primary tumors. The Consensus approaches to best practice management of gastrointestinal stromal tumors, published in this journal in 2008, provided guidance for the management of GIST to both clinicians and regulatory authorities. Since then, clinical trials have demonstrated the benefit of adjuvant imatinib in high-risk patients, and mature data from advanced GIST studies suggest that a small but significant proportion of patients with advanced disease can achieve long-term benefit with ongoing imatinib treatment. Other evolving management strategies include the controversial use of palliative or debulking surgery to improve outcomes in advanced GIST and the development of promising new multikinase inhibitors, such as regorafenib, which has established benefit in the third-line setting. This review provides an update of recent developments in GIST management and discusses new controversies that these advances have generated. © 2014 Wiley Publishing Asia Pty Ltd.
|
|
Nova |
2013 |
Ackland S, Goldstein D, McJannett M, 'Forty years of COSA - Contributions to oncology teaching and research', Cancer Forum, 37 238-242 (2013) [C2] |
|
Nova |
2013 |
Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, et al., 'Current opinion on optimal treatment for colorectal cancer', EXPERT REVIEW OF ANTICANCER THERAPY, 13 597-611 (2013) [C1]
|
|
Nova |
2013 |
Ackland S, Fukuda Y, '2012: Year in Review from dragons to snakes', Asia-Pacific Journal of Clinical Oncology, 9 1-1 (2013) [C3]
|
|
Nova |
2012 |
Ackland S, Fukuda Y, '2011: Year in Review - from rabbits to dragons', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 8 1-2 (2012)
|
|
|
2012 |
Goldstein D, Spry N, Cummins MM, Brown C, Van Hazel GA, Carroll S, et al., 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106 61-69 (2012) [C1]
|
|
Nova |
2012 |
Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al., 'Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04', Journal of Clinical Oncology, 30 3827-3833 (2012) [C1]
|
|
Nova |
2012 |
Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, et al., 'Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C', ANNALS OF ONCOLOGY, 23 1531-1536 (2012) [C1]
|
|
|
2012 |
Zdenkowski N, Chen S, Van Der Westhuizen A, Ackland S, 'Curative strategies for liver metastases from colorectal cancer: A review', Oncologist, 17 201-211 (2012) [C1]
|
|
Nova |
2012 |
Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, Sakoff JA, 'Predicting 5-Fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length - A multivariate analysis', British Journal of Cancer, 107 1525-1533 (2012) [C1]
|
|
Nova |
2012 |
Ackland S, Fukuda Y, '2011: Year in review - From rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2012) [C3] |
|
Nova |
2011 |
Garg MB, Sakoff JA, Ackland S, 'A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879 2201-2205 (2011) [C1]
|
|
Nova |
2011 |
Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, et al., 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129 467-476 (2011) [C1]
|
|
|
2011 |
Ackland S, 'Cancer in Australia: A model for other Asia-Pacific countries', Asia-Pacific Journal of Clinical Oncology, 7 323-324 (2011) [C3]
|
|
|
2011 |
Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al., 'Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC).', J Clin Oncol, 29 510 (2011) |
|
|
2011 |
Agrez M, Garg M, Dorahy D, Ackland S, 'Synergistic anti-tumor effect of cisplatin when combined with an anti-src kinase integrin-based peptide', Journal of Cancer Therapy, 2 295-301 (2011) [C1]
|
|
|
2011 |
Vilain RE, Dudding TE, Braye SG, Groombridge C, Meldrum C, Spigelman AD, et al., 'Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome?', Clinical Genetics, 79 554-560 (2011) [C3]
|
|
|
2011 |
Garg MB, Ackland S, 'Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect', Cancer Chemotherapy and Pharmacology, 67 963-966 (2011) [C1]
|
|
Nova |
2011 |
Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland S, Van Hazel G, et al., 'Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 67 519-525 (2011) [C1]
|
|
Nova |
2011 |
Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al., 'Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)', JOURNAL OF CLINICAL ONCOLOGY, 29 (2011) [E3]
|
|
|
2011 |
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland S, Fitzharris B, et al., 'Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer', Journal of Clinical Oncology, 29 4498-4504 (2011) [C1]
|
|
Nova |
2010 |
Robson M, 'COSA 37th 2010 Annual Scientific Meeting 9-11 November 2010 Melbourne Convention & Exhibition Centre Abstracts', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 6 100-253 (2010) |
|
|
2010 |
Della-Fiorentina S, 'Welcome', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 6 1-1 (2010)
|
|
|
2010 |
'Special Issue: Medical Oncology Group of Australia Incorporated and the Private Cancer Physicians of Australia Joint Scientific Meeting, Personalised Medical Oncology, 11-13 August 2010, Four Seasons Hotel, Sydney, NSW, Australia, Program and Abstracts', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 6 37-60 (2010) |
|
|
2010 |
Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, Van Hazel GA, et al., 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study', Journal of Clinical Oncology, 28 3191-3198 (2010) [C1]
|
|
Nova |
2010 |
De Bock CE, Garg ML, Scott NM, Sakoff JA, Scorgie FE, Ackland S, Lincz L, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, 1-8 (2010) [C1]
|
|
Nova |
2009 |
Ackland S, Bull JM, Boyle FM, 'Nab-Paclitaxel: A bright new sparc in taxane therapy of cancer', Asia-Pacific Journal of Clinical Oncology, 5 147-150 (2009) [C1]
|
|
Nova |
2009 |
Ackland S, 'Molecular biomarkers in non-small cell lung cancer: Pointing the way to better outcomes from treatment', Asia-Pacific Journal of Clinical Oncology, 5 213-214 (2009) [C3]
|
|
Nova |
2009 |
Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, et al., 'GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC).', J Clin Oncol, 27 4616 (2009) |
|
|
2009 |
Fisch M, 'F1000 highlights', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 5 (2009) |
|
|
2009 |
Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, et al., 'Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer', ONCOLOGY, 77 113-119 (2009) [C1]
|
|
|
2008 |
Ackland S, Tracey E, 'Cancer registries: Their role in health care delivery in the Asia-Pacific region', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 4 71-74 (2008) [C3]
|
|
|
2008 |
Vilain RE, Ackland S, 'Gastrointestinal stromal tumors - A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?', Asia-Pacific Journal of Clinical Oncology, 4 185-187 (2008) [C3] |
|
|
2008 |
Hill TA, Stewart SG, Gordon CP, Ackland SR, Gilbert J, Sauer B, et al., 'Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition', ChemMedChem, 3 1878-1892 (2008) [C1]
|
|
|
2007 |
The International Breast Cancer Study Group, Forbes JF, 'Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93', Annals of Oncology, 18 1177-1184 (2007) [C1]
|
|
|
2007 |
Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity', Bioorganic and Medicinal Chemistry Letters, 17 3392-3397 (2007) [C1]
|
|
Nova |
2007 |
Hill TA, Stewart SG, Ackland S, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation', Bioorganic and Medicinal Chemistry, 15 6126-6134 (2007) [C1]
|
|
Nova |
2007 |
Stewart SG, Hill TA, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity', Bioorganic and Medicinal Chemistry, 15 7301-7310 (2007) [C1]
|
|
|
2007 |
Temmink OH, Hoebe EK, Van Der Born K, Ackland S, Fukushima M, Peters GJ, 'Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells', British Journal of Cancer, 96 231-240 (2007) [C1]
|
|
|
2007 |
Lincz L, Scorgie FE, Garg MB, Ackland S, 'Identification of a novel single nucleotide polymorphism in the second tandem repeat sequence of the thymidylate synthase 2R allele', International Journal of Cancer, 120 1930-1934 (2007) [C1]
|
|
|
2007 |
Lincz L, Scorgie FE, Garg ML, Ackland S, 'Reply to the letter to the editor 'Classification of thymidylate synthase gene enhancer region polymorphisms'', International Journal of Cancer, 121 2581-2582 (2007) [C3]
|
|
|
2007 |
Young JM, Leong DC, Armstrong K, O'Connell D, Armstrong BK, Spigelman AD, et al., 'Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study', Medical Journal of Australia, 186 292-295 (2007) [C1]
|
|
|
2007 |
Carrington C, Carlton J, Ackland S, 'Preventing chemotherapy errors: Implementing system changes', Asia-Pacific Journal of Clinical Oncology, 3 57-58 (2007) [C3] |
|
|
2007 |
Davis AJ, Brew S, Gebski VJ, Lewis CR, Moylan E, Parnis FX, Ackland S, 'Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 3 37-43 (2007) [C1]
|
|
|
2007 |
Findlay M, Sharples K, Riley GA, Simpson A, Ackland S, Hall K, et al., 'Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer', Asia-Pacific Journal of Clinical Oncology, 3 99-105 (2007) [C1]
|
|
|
2006 |
Goldstein D, Ackland S, Bell DR, Olver IN, Davis ID, Rosenthal MA, et al., 'Phase II study of vinflunine in patients with metastatic renal cell carcinoma', Investigational New Drugs, 24 429-434 (2006) [C1]
|
|
|
2006 |
Davis AJ, Lewis CR, Moylan EJ, Parnis FX, Brew SE, Ackland SP, 'A phase II multicenter study of combination chemotherapy with capecitabine (C) and intravenous (iv) vinorelbine (V) in patients (pts) with pretreated metastatic breast cancer (MBC).', J Clin Oncol, 24 10665 (2006) |
|
|
2006 |
Sobrero A, Ackland S, Carrion RP, Chiara S, Clarke S, Giron CG, et al., 'Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.', J Clin Oncol, 24 3544 (2006) |
|
|
2006 |
Wong M, Balleine RL, Blair EYL, McLachlan AJ, Ackland S, Garg M, et al., 'Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer', Journal of Clinical Oncology, 24 2448-2455 (2006) [C1]
|
|
Nova |
2006 |
Ackland S, 'Cervical carcinoma: A common and preventable problem in developing countries (Editorial)', Asia-Pacific Journal of Clinical Oncology, 2 69-70 (2006) [C3]
|
|
|
2006 |
Ackland S, Clarke SJ, Beale P, Peters GJ, 'Thymidylate synthase inhibitors', Update on Cancer Therapeutics, 1 403-427 (2006) [C1]
|
|
|
2005 |
Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, et al., 'A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer', British Journal of Cancer, 93 1236-1243 (2005) [C1]
|
|
|
2005 |
Odelli C, Burgess D, Bateman L, Hughes A, Ackland S, Gillies J, Collins CE, 'Nutrition Support Improves Patient Outcomes, Treatment Tolerance and Admission Characteristics in Oesophageal Cancer', Clinical Oncology, 17 639-645 (2005) [C1]
|
|
Nova |
2005 |
Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al., 'Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial', Lancet Oncology, 6 659-668 (2005) [C1]
|
|
|
2004 |
Lincz L, Scorgie F, Sakoff J, Fagan K, Ackland S, Enno A, 'Telomere length predicts neutrophil recovery in absence of G-CSF after autologous peripheral blood stem cell transplantation', Bone Marrow Transplant, 34 439-445 (2004) [C1]
|
|
|
2004 |
Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, et al., 'Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients', Clinical and Experimental Pharmacology and Physiology, 31 677-682 (2004) [C1]
|
|
|
2004 |
Sakoff JA, Howitt IJ, Ackland S, McCluskey A, 'Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition', Cancer Chemotherapy and Pharmacology, 53 225-232 (2004) [C1]
|
|
Nova |
2004 |
O'Brien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al., 'Reduced cardiotoxicity and comparable efficacy in a phase 3 trial of pegylated liposomal doxorubicine HCI (CAELYX / Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer', Annals of Oncology, 15 440-449 (2004) [C1]
|
|
|
2003 |
Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al., 'A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy', ANNALS OF ONCOLOGY, 14 29-35 (2003)
|
|
|
2003 |
Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31 68-79 (2003) [C1]
|
|
Nova |
2003 |
Denham J, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lam D, et al., 'Relapse patterns after chemo-radiation for carcinoma of the oesophagus', Clinical Oncology, 15 98-108 (2003) [C1]
|
|
Nova |
2002 |
Sakoff J, Ackland S, Baldwin ML, Atherton MA, McCluskey A, 'Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues', Investigational New Drugs, 20 1-11 (2002) [C1]
|
|
|
2002 |
Ackland SP, Clarke SJ, Beale P, Peters GJ, 'Thymidylate synthase inhibitors.', Cancer chemotherapy and biological response modifiers, 20 1-36 (2002)
|
|
|
2002 |
Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Milward MJ, Ackland S, 'Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na ve patients with advanced non-small-cell lung cancer', Annals of Oncology, 13 737-741 (2002) [C1]
|
|
|
2002 |
Rischin D, Ackland S, Smith J, Garg MB, Clarke SJ, Millward MJ, et al., 'Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with G-CSF but not with prophylactic antibiotics', Annals of Oncology, 13 1810-1818 (2002) [C1]
|
|
|
2002 |
McCluskey A, Ackland S, Gardiner E, Walkom CC, Sakoff J, 'The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16 291-303 (2002) [C1]
|
|
|
2002 |
Garg MB, Sevester JC, Sakoff JA, Ackland SP, 'Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity', JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 774 223-230 (2002)
|
|
|
2002 |
Garg MB, Sevester JC, Sakoff JA, Ackland S, 'Rapid and simple chromatographic method for the determination of uracil and dihydrouracil plasma levels: A potential pretreatment predictor of 5FU toxicity', Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Science, 774 223-230 (2002) [C1] |
|
|
2002 |
Sakoff J, De Waal E, Garg M, Denham J, Scorgie F, Enno A, et al., 'Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood', Leukemia and Lymphoma, 43(10) 2017-2020 (2002) [C1]
|
|
|
2002 |
Forbes JF, International Breast Cancer Study Group, 'Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial', Journal of the National Cancer Institute, 94 1054-1065 (2002)
|
|
|
2002 |
Marx G, Lewis C, Hall K, Levi J, Ackland S, 'Phase I study of docetaxel plus ifosfamide in patients with advanced cancer', British Journal of Cancer, 87 846-849 (2002) [C1]
|
|
|
2002 |
Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, et al., 'Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines', British Journal of Cancer, 86 1367-1372 (2002) [C1]
|
|
|
2001 |
Ackland S, Anton A, Breitbach G, Colajori E, Tursi J, Delfino C, et al., 'Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophoshamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study', Journal of Clinical Oncology, 19 943-953 (2001) [C1]
|
|
|
2001 |
McCluskey A, Walkom CC, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters, 11 2941-2946 (2001) [C1]
|
|
Nova |
2000 |
Sanson-Fisher RW, Girgis A, Boyes A, Bonevski B, Burton L, Cook P, et al., 'The unmet supportive care needs of patients with cancer', Cancer, 88 225-236 (2000) [C1]
|
|
|
2000 |
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al., 'Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.', NEW ENGLAND JOURNAL OF MEDICINE, 343 905-914 (2000)
|
|
|
2000 |
Peters G, De Bruin M, Fukushima M, Van Triest B, Hoekman K, Pinedo H, Ackland S, 'Thymidine phosphorylase in angiogenesis and drug resistance', Advances in Experimental Medicine and Biology, 486 291-294 (2000) [C2] |
|
|
2000 |
Peters GJ, van der Wilt CL, van Moorsel CJA, Kroep JR, Bergman AM, Ackland SP, 'Basis for effective combination cancer chemotherapy with antimetabolites', PHARMACOLOGY & THERAPEUTICS, 87 227-253 (2000)
|
|
|
2000 |
Sakoff J, Ackland S, 'Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells', Cancer Chemotherapy and Pharmacology, 46 477-487 (2000) [C1]
|
|
|
2000 |
Garg M, Ackland S, 'Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine', Journal of Chromatography B, 748 383-388 (2000) [C1]
|
|
|
2000 |
Sakoff JA, McCluskey A, Sims ATR, Stewart JF, Ackland SP, 'A counter intuitive therapy for the treatment of cancer: Inhibition of protein phosphatases 1 and 2A by cantharidin (Spanish Fly) analogues.', CLINICAL CANCER RESEARCH, 6 4495S-4495S (2000)
|
|
|
2000 |
Bonevski B, Sanson-Fisher RW, Girgis A, Burton L, Cook P, Boyes A, et al., 'Evaluation of an instrument to assess the needs of patients with cancer', Cancer, 88 217-225 (2000) [C1]
|
|
|
1999 |
Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MHN, Olver IN, et al., 'Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer', JOURNAL OF CLINICAL ONCOLOGY, 17 2355-2364 (1999)
|
|
|
1999 |
Ackland SP, Peters GJ, 'Erratum: Thymidine phosphorylase: Its role in sensitivity and resistance to anticancer drugs (Drug Resistance Updates (1999) 2 (205-214))', Drug Resistance Updates, 2 345 (1999) |
|
|
1999 |
Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al., 'Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer', Australasian Radiology, 43 220-226 (1999)
The purpose of the present paper was to evaluate treatment outcome after conservative breast surgery or mastectomy followed by simultaneous adjuvant radiotherapy and cyclophospham... [more]
The purpose of the present paper was to evaluate treatment outcome after conservative breast surgery or mastectomy followed by simultaneous adjuvant radiotherapy and cyclophosphamide, methotrexate and fluorouracil (CMF) therapy. Two hundred and sixty eight (268) patients were treated at two Australian and two New Zealand centres between 1981 and July 1995. One hundred and sixty-nine patients underwent conservation surgery and 99 had mastectomies. Median follow-up was 53 months. Conventionally fractionated radiation was delivered simultaneously during the first two cycles of CMF, avoiding radiation on the Fridays that the intravenous components of CMF were delivered. In conservatively treated patients, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 34.5 ± 5.2%, 25.4 ± 4.5% and 75.5 ± 4.8%, respectively. Crude incidence of local relapse at 4 years was 6.3% and at regional/distant sites was 26.3%. Highest grades of granulocyte toxicity (< 0.5 x 109/L), moist desquamation, radiation pneumonitis and persistent breast oedema were recorded in 10.7, 8.5, 8.9 and 17.2%, respectively. In patients treated by mastectomy, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 59.7 ± 7.3%, 56.7 ± 7.4% and 50.1 ± 7%. The crude incidence of local relapse at 4 years was 5.6% and at regional/distant sites it was 45.7%. The issue of appropriate timing of adjuvant therapies has become particularly important with the increasing acknowledgement of the value of anthracycline-based regimens. For women in lower risk categories (e.g. 1-3 nodes positive or node negative), CMF may offer a potentially better therapy, particularly where breast-conserving surgical techniques have been used. In such cases CMF allows the simultaneous delivery of radiotherapy with the result of optimum local control, without compromise or regional or systemic relapse rates. Further randomized trials that directly address the optimal integration of the two modalities, such as the one carried out in Boston, are clearly necessary.
|
|
|
1999 |
Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P, Spry NA, 'Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy', EUROPEAN JOURNAL OF CANCER, 35 921-927 (1999)
|
|
|
1999 |
Ackland S, Rischin D, Beith J, Gupta S, Wyatt S, Davison J, et al., 'Phase I study of docetaxel epirubicin and cyclophosphamide (TEC) in patients with advanced cancer (AC)', EUROPEAN JOURNAL OF CANCER, 35 S292-S292 (1999)
|
|
|
1999 |
Newell SA, Sanson-Fisher RW, Girgis A, Ackland S, 'The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study', European Journal of Cancer Care, 8 73-82 (1999) [C1]
|
|
|
1999 |
Ackland SP, Peters GJ, 'Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs', DRUG RESISTANCE UPDATES, 2 205-214 (1999)
|
|
|
1998 |
van der Heijden M, Ackland SP, Deveridge S, 'Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy - A case report and review of the literature', ACTA ONCOLOGICA, 37 107-109 (1998)
|
|
|
1998 |
Ackland SP, 'Drug treatment of breast cancer', Australian Prescriber, 21 15-19 (1998)
The medical treatments available for breast cancer include endocrine agents, cytotoxic chemotherapy and adjunctive treatments. New antioestrogens and aromatase inhibitors offer a ... [more]
The medical treatments available for breast cancer include endocrine agents, cytotoxic chemotherapy and adjunctive treatments. New antioestrogens and aromatase inhibitors offer a greater breadth of endocrine therapy and lower toxicity than some older drugs. Anthracyclines (doxorubicin or epirubicin) are now the major components of first-line combination chemotherapy. Many new cytotoxic drugs are currently undergoing phase III clinical trials and may ultimately find a role in the management of advanced disease, In adjuvant therapy of early breast cancer, either hormonal therapy, chemotherapy or both are needed to provide optimal reduction of the risk ofrecurrence.
|
|
|
1998 |
Gurney HP, Ackland S, Gebski V, Farrell G, 'Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation', JOURNAL OF CLINICAL ONCOLOGY, 16 2299-2304 (1998)
|
|
|
1998 |
Garg M, Ackland S, 'A sensitive method for the determination of docetaxel (Taxotere (R)) in human plasma by high performance liquid chromatography', ANNALS OF ONCOLOGY, 9 94-94 (1998) |
|
|
1998 |
Ackland S, Garg M, van Moorsel CJA, Kuiper CM, Smid K, Peters GJ, 'Tomudex and cisplatin have additive cytotoxicity and no biochemical interaction in ovarian cancer cell lines', ANNALS OF ONCOLOGY, 9 155-155 (1998)
|
|
|
1998 |
Clarke S, Millward M, Findlay M, Ackland S, Hosie D, Abratt R, Goedhals L, 'Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC)', ANNALS OF ONCOLOGY, 9 86-87 (1998)
|
|
|
1998 |
van Laar JAM, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ, 'Comparison of 5-fluoro-2 '-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer', EUROPEAN JOURNAL OF CANCER, 34 296-306 (1998)
|
|
|
1997 |
Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, et al., 'A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: Preliminary results', SEMINARS IN ONCOLOGY, 24 5-9 (1997)
|
|
|
1997 |
Ackland SP, Garg MB, Dunstan RH, 'Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography', ANALYTICAL BIOCHEMISTRY, 246 79-85 (1997)
|
|
|
1997 |
Leong DCS, Kinlay S, Ackland S, Bonaventura A, Stewart JF, 'Low-risk febrile neutropenia in a medical oncology unit', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 27 403-407 (1997)
|
|
|
1997 |
Liu JP, Yajima Y, Li H, Ackland S, Akita Y, Stewart J, Kawashima S, 'Molecular interactions between dynamin and G-protein beta gamma-subunits in neuroendocrine cells', MOLECULAR AND CELLULAR ENDOCRINOLOGY, 132 61-71 (1997)
|
|
|
1997 |
Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, et al., 'Paclitaxel as first-line treatment for metastatic breast cancer', ONCOLOGY, 11 19-23 (1997)
When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to com... [more]
When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to compare paclitaxel with standard chemotherapy as front-line therapy for this disease. Patients with measurable or evaluable metastatic breast cancer, no prior chemotherapy for metastatic disease, and an Eastern Cooperative Oncology Group performance status of 0 to 2 were randomized to receive paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles (6 months) or standard treatment with oral cyclophosphamide (Cytoxan) 100 mg/m2/d days 1 through 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5-fluorouracil 600 mg/m2 days 1 and 8, and oral prednisolone 40 mg/m2/d (CMFP) days 1 through 14 for six cycles (6 months). Patients whose disease progressed or relapsed were recommended to receive second-line epirubicin. Accrual has been completed with 208 patients randomized, but a preplanned interim analysis of the first 100 patients is reported here. Analysis of quality of life, assessed by a linear analogue scale and overall quality of life indices, is ongoing. Objective response occurred in 31% (confidence interval, 19% to 45%) with paclitaxel and 35% (confidence interval, 22% to 51%) with CMFP with stable disease in an additional 33% and 29%, respectively. Median time to progression was 5.5 months for paclitaxel-treated patients and 6.4 months for those given CMFP, with median survival durations of 17.3 and 11.3 months, respectively. Grades 3 and 4 neutropenia occurred in 64% of patients treated with paclitaxel and in 63% treated with CMFP. However, febrile neutropenia was the primary reason for hospitalization in 1% of paclitaxel courses, compared with 8% of CMFP courses. Nine percent of the patients had major infections with CMFP, but none were seen with paclitaxel. Moderate or severe mucositis occurred in 13% of paclitaxel-treated and 27% of CMFP-treated patients. Alopecia and peripheral neuropathy were more common with paclitaxel Quality of life assessments in the first 100 patients suggest better overall results on paclitaxel treatment as compared with CMFP. Preliminary analyses suggest that single-agent paclitaxel is well tolerated and provides comparable control of metastatic cancer to CMFP combination therapy when used as front-line treatment.
|
|
|
1996 |
Peters GJ, Ackland SP, 'New antimetabolites in preclinical and clinical development', Expert Opinion on Investigational Drugs, 5 637-679 (1996)
A number of new antimetabolites successfully entered clinical practice over the last ten years, and several more are awaiting registration in a number of countries. In addition, s... [more]
A number of new antimetabolites successfully entered clinical practice over the last ten years, and several more are awaiting registration in a number of countries. In addition, several compounds have been developed for use in combination with established anticancer agents (primarily 5-fluorouracil [5-FU] or one of its analogues). The most successful group of new anticancer agents are the deoxynucleoside analogues (e.g., cladribine, fludarabine, 5-aza-2'-deoxycytidine and gemcitabine), which require activation by one of the four deoxynucleoside kinases present in mammalian cells. However, a further analogue, pentostatin, is a potent inhibitor of adenosine deaminase, leading to an increase in deoxyadenosine, which becomes toxic after conversion to the deoxynucleotide. Other interesting compounds require activation by a viral deoxynucleoside kinase; the Herpes Simplex Virus (HSV)-thymidine kinase (TK), e.g., ganciclovir. A number of compounds have been developed to modulate the activity of 5-FU, e.g., ethynyluracil (EU) and 5-chloro-2,4- dihydroxypyridine (CDHP) inhibit dihydropyrimidine dehydrogenase (DPD), thus, preventing degradation of 5-FU and increasing its bioavailability. Prodrugs of 5-FU have attracted much more attention recently than in the 1980s: e.g., ftorafur, present in (UFT) [1-(2-tetrahydrofuryl)-5-fluorouracil:uracil (1:4)] and S-1, and capecitabine, a prodrug of the 5-FU precursor 5'-deoxy-5- fluorouridine. Antifolates have also received a lot of attention and several new antifolates have been developed over the last ten years, of which the most interesting are the new thymidylate synthase (TS) inhibitors. Many of these have entered clinical development and some have even been registered (e.g., tomudex in England). These compounds include tomudex (ZD1694, formerly ICI-D1694; Zeneca), LY231514 (Eli Lilly), 1843U89 (formerly BW1843U89; Glaxo Wellcome), and AG331 and AG337 (Thymitaq; Agouron). AG337 is of special interest, since it appears to exhibit a different pattern of activity to that of tomudex. A new group of antifolates in development, and generating considerable interest, are the glycinamide ribonucleotide transferase (GARTF) inhibitors: e.g., lometrexol and LY309887 (Eli Lilly), and AG2032 and AG2034 (Agouron). However, the place of these compounds in therapy (i.e., as single agents or as modulating agents) remains unclear at present. In summary, rational drug design over the last few decades has led to the introduction of a number of antimetabolites with significant antitumour activity not only against leukaemia, but also against several solid tumours. © 1996 Ashley Publications Ltd.
|
|
|
1996 |
Cunningham D, Zalcberg JR, Rath U, Oliver I, vanCutsem E, Svensson C, et al., 'Final results of a randomised trial comparing 'Tomudex'(R) (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer', ANNALS OF ONCOLOGY, 7 961-965 (1996)
|
|
|
1995 |
DENHAM JW, HAMILTON CS, CHRISTIE D, OBRIEN M, BONAVENTURA A, STEWART JF, et al., 'SIMULTANEOUS ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER - TOXICITY AND DOSE MODIFICATION - A TRANS-TASMAN RADIATION ONCOLOGY GROUP MULTI-INSTITUTION STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 31 305-313 (1995)
|
|
|
1995 |
BURMEISTER BH, DENHAM JW, OBRIEN M, JAMIESON GG, GILL PG, DEVITT P, et al., 'COMBINED-MODALITY THERAPY FOR ESOPHAGEAL-CARCINOMA - PRELIMINARY-RESULTS FROM A LARGE AUSTRALASIAN MULTICENTER STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32 997-1006 (1995)
|
|
|
1995 |
DALLEY D, LEVI J, BELL D, GREEN M, SHERMAN P, ZALCBERG J, et al., 'PHASE-III RANDOMIZED STUDY OF 2 FLUOROURACIL COMBINATIONS WITH EITHER INTERFERON-ALFA-2A OR LEUCOVORIN FOR ADVANCED COLORECTAL-CANCER', JOURNAL OF CLINICAL ONCOLOGY, 13 921-928 (1995)
|
|
|
1995 |
Cunningham D, Zalcberg JR, Rath U, Olver I, VanCutsem E, Svensson C, et al., ''Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia', EUROPEAN JOURNAL OF CANCER, 31A 1945-1954 (1995)
|
|
|
1993 |
Ackland SP, Hamilton CS, Joseph DJ, Denham JW, 'Phase I/II study of concurrent weekly carboplatin and radiation therapy in advanced head and neck cancer', Clinical Oncology, 5 133-138 (1993)
Thirty-two patients with locally advanced head and neck cancer have been treated with concurrent weekly carboplatin and conventional radiation therapy (RT) (2 Gy fractions 4-5 day... [more]
Thirty-two patients with locally advanced head and neck cancer have been treated with concurrent weekly carboplatin and conventional radiation therapy (RT) (2 Gy fractions 4-5 days/week to a total dose of 64-70 Gy over 7-8 weeks) in a Phase I/II study. Carboplatin was administered weekly during RT at doses of 75-150 mg/m2//wk as a 1-hour infusion. The maximum tolerated dose of carboplatin was 130 mg/m2//wk, with myelosuppression, predominantly neutropenia, being dose limiting. Other systemic toxicities were insignificant and no overlapping toxicity was evident. Ultimate locoregional control and survival probabilities were disappointing. It is suggested that either further studies using radiation and carboplatin at the dose 130 mg/m2//wk, or variations on dose and scheduling be performed prior to the instigation of Phase III studies. © 1993 The Royal College of Radiologists.
|
|
|
1993 |
Cooper SG, Bonaventura A, Ackland SP, Joseph DJ, Stewart JF, Hamilton CS, Denham JW, 'Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: A phase II study', Clinical Oncology, 5 169-173 (1993)
Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival. We wished to find out if we could safely give concurrent ra... [more]
Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival. We wished to find out if we could safely give concurrent radiotherapy and 5-fluorouracil (5-FU) modulated by leucovorin (LV) in 3 settings: pre-operatively, adjuvantly and in recurrent disease. A total of 39 patients were treated, 11 preoper-atively, 17 adjuvantly and 11 with recurrent disease. There were 26 males and 13 females with a median age of 64 years. The median radiotherapy (RT) dose was 45 Gy/25 fractions/1.8 Gy per fraction (range 25-63 Gy). Chemotherapy consisted of LV 80 mg/m2 i.v. infusion over 1.5 hours followed by 5-FU 400 mg/m2 i.v. bolus, both given once a week. The median number of cycles was 8 (range 3-12). Diarrhoea was the main toxicity, and was encountered in 30 patients (77%): grade 1 in 3 (8%), grade 2 in 12 (30%), grade 3 in 11 (28%), and grade 4 in 4 (10%). This required 18 (46%) patients to have modifications to their RT (20% had breaks and 26% ceased at doses <45 Gy). Nine patients (23%) had modifications in the chemotherapy (10% had breaks and 13% received <6 cycles). Encouraging responses were seen in the preoperative setting. Concurrent RT and 5-FU/LV, as given in this schedule, results in an unacceptable incidence of diarrhoea, limiting both the total dose of RT and chemotherapy that can be delivered, particulary in patients who have had previous surgery. © 1993 The Royal College of Radiologists.
|
|
|
1992 |
ROSENTHAL MA, RAGHAVAN D, STUARTHARRIS R, ACKLAND S, GRYGIEL J, 'THE TREATMENT OF DISSEMINATED PROSTATE-CANCER WITH ESTRAMUSTINE', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 62 871-873 (1992)
|
|
|
1990 |
JOSEPH DJ, HAMILTON CS, DENHAM JW, ACKLAND SP, STEWART JF, 'WHITHER SCREENING MAMMOGRAPHY IN AUSTRALIA - ESTABLISHING A SATISFACTORY BASIS FOR FUNDING', MEDICAL JOURNAL OF AUSTRALIA, 152 545-546 (1990)
|
|
|
1989 |
ACKLAND SP, RATAIN MJ, VOGELZANG NJ, CHOI KE, RUANE M, SINKULE JA, 'PHARMACOKINETICS AND PHARMACODYNAMICS OF LONG-TERM CONTINUOUS-INFUSION DOXORUBICIN', CLINICAL PHARMACOLOGY & THERAPEUTICS, 45 340-347 (1989)
|
|
|
1989 |
COOPER SG, DENHAM JW, HAMILTON CS, JOSEPH DJ, STEWART JF, ACKLAND SP, 'THE PRICE OF A FALSE-NEGATIVE RESULT OF MAMMOGRAPHY AND AN OVERENTHUSIASTIC LAY PRESS', MEDICAL JOURNAL OF AUSTRALIA, 150 664-664 (1989)
|
|
|
1988 |
ACKLAND SP, BUR ME, ADLER SS, ROBERTSON M, BARON JM, 'WHITE BLOOD-CELL APLASIA ASSOCIATED WITH THYMOMA', AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 89 260-263 (1988)
|
|
|
1988 |
ACKLAND SP, SCHILSKY RL, BECKETT MA, WEICHSELBAUM RR, 'SYNERGISTIC CYTO-TOXICITY AND DNA STRAND BREAK FORMATION BY BROMODEOXYURIDINE AND BLEOMYCIN IN HUMAN-TUMOR CELLS', CANCER RESEARCH, 48 4244-4249 (1988)
|
|
|
1988 |
ACKLAND SP, CHOI KE, RATAIN MJ, EGORIN MJ, WILLIAMS SF, SINKULE JA, BITRAN JD, 'HUMAN-PLASMA PHARMACOKINETICS OF THIOTEPA FOLLOWING ADMINISTRATION OF HIGH-DOSE THIOTEPA AND CYCLOPHOSPHAMIDE', JOURNAL OF CLINICAL ONCOLOGY, 6 1192-1196 (1988)
|
|
|
1988 |
Ackland SP, Schilsky RL, Beckett MN, Weichselbaum RR, 'Synergistic Cytotoxicity and DNA Strand Break Formation by Bromodeoxyuridine and Bleomycin in Human Tumor Cells', Cancer Research, 48 4256-4260 (1988)
5-Bromo-2¿-deoxyuridiiie (BrdUrd) is a thymidine analogue whose cellular effects are related to its incorporation into DNA. BrdUrd is a known radiosensitizing agent that could pot... [more]
5-Bromo-2¿-deoxyuridiiie (BrdUrd) is a thymidine analogue whose cellular effects are related to its incorporation into DNA. BrdUrd is a known radiosensitizing agent that could potentially enhance the activity of chemotherapeutic agents that interact directly with DNA. Therefore we studied the interaction of BrdUrd and bleomycin in a human head and neck squamous carcinoma cell line, SQ20B. Using a colony-forming assay and analyzing results by the median-effect method, we have shown that there is synergistic cytotoxicity between BrdUrd and bleomycin. Synergism is evident when BrdUrd is administered prior to bleomycin or when the two drugs are applied simultaneously and is evident at a variety of BrdUrd:bleomycin concentration ratios. Alkaline elution of DNA from cells exposed to BrdUrd and bleomycin demonstrated greater single strand break formation than expected from the individual single strand break frequencies induced by each drug alone. BrdUrd did not affect the rate of repair of bleomycin-induced single strand breaks or the formation of double strand breaks. Although the mechanism of this interaction at the molecular level is unclear, our studies suggest that a direct interaction of bleomycin with BrdUrd-substituted DNA may be the cause of the synergism of these two agents. © 1988, American Association for Cancer Research. All rights reserved.
|
|
|
1987 |
ACKLAND SP, WESTBROOK CA, DIAZ MO, LEBEAU MM, ROWLEY JD, 'EVIDENCE FAVORING LINEAGE FIDELITY IN ACUTE NONLYMPHOCYTIC LEUKEMIA - ABSENCE OF IMMUNOGLOBULIN GENE REARRANGEMENTS IN FAB TYPE-M4 AND TYPE-M5', BLOOD, 69 87-91 (1987)
|
|
|
1987 |
BISHOP JF, WOLF M, MATTHEWS JP, SCOTT K, ACKLAND S, YUEN K, et al., 'RANDOMIZED, DOUBLE-BLIND, CROSSOVER STUDY COMPARING PROCHLORPERAZINE AND LORAZEPAM WITH HIGH-DOSE METOCLOPRAMIDE AND LORAZEPAM FOR THE CONTROL OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY', CANCER TREATMENT REPORTS, 71 1007-1011 (1987)
|
|
|
1987 |
ACKLAND SP, SCHILSKY RL, 'HIGH-DOSE METHOTREXATE - A CRITICAL REAPPRAISAL', JOURNAL OF CLINICAL ONCOLOGY, 5 2017-2031 (1987)
|
|
|
1985 |
ACKLAND SP, BITRAN JD, DOWLATSHAHI K, 'MANAGEMENT OF LOCALLY ADVANCED AND INFLAMMATORY CARCINOMA OF THE BREAST', SURGERY GYNECOLOGY & OBSTETRICS, 161 399-408 (1985)
|
|
|
1985 |
ACKLAND SP, HILLCOAT BL, 'IMMEDIATE HYPERSENSITIVITY TO MANNITOL - A POTENTIAL CAUSE OF APPARENT HYPERSENSITIVITY TO CISPLATIN', CANCER TREATMENT REPORTS, 69 562-563 (1985)
|
|
|
1984 |
HALLAM LJ, VANDERWEYDEN MB, ACKLAND SP, BAGNARA AS, WHITESIDE MG, 'THE BIOCHEMICAL AND CLINICAL CONSEQUENCES OF 2'-DEOXYCOFORMYCIN IN T-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA', SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 32 55-64 (1984)
|
|
|
1983 |
ACKLAND SP, BISHOP JF, WHITESIDE MG, 'ACYCLOVIR THERAPY IN PATIENTS WITH MALIGNANT DISEASE AND DISSEMINATED HERPES-ZOSTER', MEDICAL JOURNAL OF AUSTRALIA, 1 637-638 (1983)
|
|
|